Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 4/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | PLA2G4B | P0C869 | 7/20 | 0.63 |
| ▸ | THRA | P10827 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10716259 | 0.98 | RARB (0.68) | RARBPKMTSHRTP53PLA2G4B | |
| SCHEMBL9485108 | 0.94 | RARB (0.81) | RARBPKMTSHRTP53PLA2G4B | |
| Hydrochloric Acid SCHEMBL9483368 | 0.92 | RARB (0.78) | RARBPKMTSHRTP53PLA2G4B | |
| SCHEMBL9336539 | 0.91 | PLA2G4B (0.71) | RARBPKMTSHRTP53PLA2G4B | |
| SCHEMBL11867659 | 0.91 | RARB (0.59) | RARBPKMTSHRTP53PLA2G4B | |
| SCHEMBL20502046 | 0.89 | PKM (0.78) | RARBPKMTSHRTP53PLA2G4B | |
| SCHEMBL577687 | 0.89 | PKM (0.78) | RARBPKMTSHRTP53PLA2G4B | |
| SCHEMBL4509186 | 0.89 | PKM (0.78) | RARBPKMTSHRTP53PLA2G4B | |
| SCHEMBL13918671 | 0.89 | PKM (0.78) | RARBPKMTSHRTP53PLA2G4B | |
| SCHEMBL5851023 | 0.88 | RARB (0.77) | RARBPKMTSHRTP53PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-53127433-A | — | — | None | — | — | JP | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-20150299134-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| US-20140066455-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-8604022-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2013-12-10 | — | — | US | disclosed |
| CN-101611014-B | Amidopyrazoles as FGFR inhibitors | ASTRAZENECA AB | 2012-05-30 | — | — | CN | disclosed |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | ASTRAZENECA AB | 2012-05-24 | — | — | US | disclosed |
| US-8129391-B2 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| WO-1998016622-A1 | A METHOD FOR PREDISSOLVING DETERGENT COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1998-04-23 | — | — | WO | disclosed |
| US-5545349-A | Bleaching composition | KAO CORPORATION (JP) | 1996-08-13 | — | — | US | disclosed |
| EP-0447553-A1 | BLEACHING COMPOSITION | Kao Corporation (JP) | 1991-09-25 | — | — | EP | disclosed |
| EP-0314735-A1 | LIQUID CRYSTAL MATERIAL | THE GENERAL ELECTRIC COMPANY, p.l.c. (GB) | 1989-05-10 | — | — | EP | disclosed |
| WO-1988008870-A1 | LIQUID CRYSTAL MATERIAL | THE GENERAL ELECTRIC COMPANY, P.L.C. (GB) | 1988-11-17 | — | — | WO | disclosed |
| US-4707296-A | LIQUID CRYSTALS, OPTICAL APPARATUS | CHISSO CORPORATION (JP) | 1987-11-17 | — | — | US | disclosed |
| US-4385927-A | ETHER OF N-2,3-DICHLOROPHENYL P-HYDROXYBENZAMIDE | HODOGAYA CHEMICAL CO., LTD. (JP) | 1983-05-31 | — | — | US | disclosed |
| US-4206076-A | STABILIZERS AGAINST HEAT, LIGHT, OR OXYGEN | SANDOZ LTD. (CH) | 1980-06-03 | — | — | US | disclosed |
| US-4158011-A | LIQUID CRYSTALS | CHISSO CORPORATION (JP) | 1979-06-12 | — | — | US | disclosed |
| JP-S53127433-A | P-(BETA-ALKOXY) ETHOXYBENZOIC ACIDS | CHISSO CORP | 1978-11-07 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | RARB 2308/4885PKM 1006/4885TSHR 3669/4885 |
| US-20140066455-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | RARB 2118/4885PKM 1436/4885TSHR 4034/4885 |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RARB 2611/4885PKM 231/4885TSHR 3921/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | RARB 2118/4885PKM 1436/4885TSHR 4034/4885 |
| US-20150299134-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | RARB 2118/4885PKM 1436/4885TSHR 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.